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a b s t r a c t
Cholesterolomics can be regarded as the identiﬁcation and quantiﬁcation of cholesterol, its precursors
post squalene, and metabolites of cholesterol and of its precursors, in a biological sample. These mole-
cules include 1,25-dihydroxyvitamin D3, steroid hormones and bile acids and intermediates in their
respective biosynthetic pathways. In this short article we will concentrate our attention on intermediates
in bile acid biosynthesis pathways, in particular oxysterols and cholestenoic acids. These molecular
classes are implicated in the aetiology of a diverse array of diseases including autoimmune disease,
Parkinson's disease, motor neuron disease, breast cancer, the lysosomal storage disease Niemann-Pick
type C and the autosomal recessive disorder Smith-Lemli-Opitz syndrome. Mass spectrometry (MS) is
the dominant technology for sterol analysis including both gas-chromatography (GC)-MS and liquid
chromatography (LC)-MS and more recently matrix-assisted laser desorption/ionisation (MALDI)-MS for
tissue imaging studies. Here we will discuss exciting biological ﬁndings and recent analytical
improvements.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Gas chromatography e mass spectrometry (GC-MS) with the
utilisation of stable-isotope labelled standards is the gold standard
methodology for the analysis of neutral cholesterol metabolites
[1e3]. Acidic metabolites are efﬁciently analysed by liquid chro-
matography (LC)-MS, where optimal analysis is similarly per-
formedwith the use of isotope labelled standards [4,5]. GC-MSwith
appropriate derivatisation is also suitable for analysis of acidic
metabolites [6], while LC-MS can also be used for the analysis of
neutrals with appropriate ionisation additives or derivatisation
methods [7e12]. GC-MS methods tend to incorporate a saponiﬁ-
cation step and measure a combination of both esteriﬁed and non-
esteriﬁed sterols, while LC-MS methods may or may not include
base hydrolysis. Using MS methods, a number of exciting discov-
eries have recently been made. In this short review we will cover
the discoveries of most interest to the authors and discuss analyt-
ical improvements since our review of analytical methods in 2011
[7].
1.1. 25-Hydroxycholesterol and immunity
25-Hydroxycholesterol (25-HC) is formed from cholesterol by
the enzyme cholesterol 25-hydroxylase (CH25H) and also by other
sterol hydroxylases as a minor side-product [13]. It can be 7a-
hydroxylated by the enzyme oxysterol 7a-hydroxylase, cyto-
chrome P450 (CYP) 7B1, to give 7a,25-dihydroxycholesterol
(7a,25-diHC, Fig. 1). Until recently 25-HC was regarded by
analytical biochemists as a minor oxysterol, present at only low
levels in plasma (ng/mL), cerebrospinal ﬂuid (CSF, < ng/mL) and
most tissues (ng/g). Note, Supplementary Tables S1 and S2 pub-
lished in Ref. [7] provide lists of literature values for oxysterols
measured prior to 2011. However, Diczfalusy et al. found that
lipopolysaccharide (LPS; endotoxin) injection to healthy volun-
teers more than doubled the plasma concentration of 25-HC,
while treatment of mouse bone-marrow derived macrophages
resulted in a 35-fold increase in expression of Ch25h [14]. This
ﬁnding strongly links 25-HC with the immune system. The oxy-
sterol measurements were made using the classical GC-MS
methodology as described by Dzeletovic et al. exploiting isotope
dilution mass spectrometry for quantiﬁcation [1]. About the same
time as Diczfalusy et al.'s study was performed, Baumann et al.
reported that activation of the Toll-like receptor 4 (TLR4) by Kdo2-
Lipid A, an LPS substructure with endotoxin activity, resulted in
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synthesis of 25-HC in mouse intraperitoneal macrophages and an
increase in expression of Ch25h [15]. Baumann et al. found that
treatment of naïve B cells with nanomolar concentrations of 25-
HC suppressed interleukin (IL)-2-mediated stimulation of B cell
proliferation, repressed activation-induced cytidine deaminase
expression, and blocked class switch recombination, leading to
markedly decreased immunoglobulin A (IgA) production [15].
They concluded that suppression of IgA class switching in B cells
by macrophage-derived 25-HC in response to TLR activation pro-
vides a mechanism for local and systemic negative regulation of
the adaptive immune response by the innate immune system [15].
In their study, oxysterol measurements were performed by LC-MS
using the methodology of McDonald et al. [16]. Dendritic cells (DC)
are antigen presenting cells of the mammalian immune system,
acting as messengers between the innate and adaptive immune
systems. Like macrophages, DCs respond to TLR activation by
increasing the expression of Ch25h [17]. Park and Scott found that
induction of Ch25h was mediated by type 1 interferons (IFNs)
through the IFN receptor (IFNR) and the JAK/STAT1 pathway
[17,18]. The three studies by Diczfalusy et al., Baumann et al. and
Park and Scott identiﬁed 25-HC as an important bioactive lipid in
the innate and adaptive immune systems and as an important
modulator of the immune response to infection [14,15,17,18].
While LPS is an endotoxin, a toxin of the bacterial cell wall, which
activates TLRs leading to transcription and translation of choles-
terol 25-hydroxylase in macrophages and secretion of 25-HC, viral
infection can result in a similar response by macrophages. Blanc
et al. showed that upon viral infection or IFN stimulation, Ch25h is
up-regulated via STAT1 activation leading to 25-HC secretion by
macrophages as a potent paracrine inhibitor of many viral in-
fections [19]. In this study Blanc et al. used LC-MS with multistage
fragmentation (MSn) exploiting “enzyme-assisted derivatisation
for sterol analysis” (EADSA, see below) to proﬁle for essentially
every known oxysterol [19,20]. Only 25-HC was secreted by
macrophages upon infection or IFN stimulation [19]. In a follow-up
study Robertson et al. found that an IFN-regulated microRNA
(miRNA), i.e. small non-coding RNA that functions in the post-
transcriptional silencing of speciﬁc genes, suppressed the choles-
terol biosynthesis pathway in activated macrophages as part of the
antiviral response [21]. This miRNA, called miR-342-5p, sup-
pressed the pathway at multiple levels: transcriptionally via
SREBF2; post-transcriptionally via another miRNA, miR-33; and
enzymatically via the genes IDI1 (isopentenyl pyrophosphate
isomerase 1) and SC4MOL (methylsterol monooxygenase 1).
SREBF2 is the gene encoding sterol regulatory-element binding
protein 2 (SREBP2), the master transcription factor regulating the
cholesterol synthesis pathway; miR-33 is located within an intron
of SREBF2 and regulates cholesterol homeostasis; while IDI1 and
SC4MOL code for enzymes in the cholesterol synthesis pathway.
Robertson et al. found that cholesterol and intermediates in its
biosynthesis were reduced as part of the macrophage IFN anti-
viral response [21]. LC-MSn was used exploiting EADSA to quan-
tify cholesterol and its precursors.
25-HC is a ligand of the liver X receptors (LXR) a and b,
members of the nuclear receptor superfamily [22] and a regulator
of the processing of SREBP2 to its active form as a transcription
factor [23]. Reboldi et al. have suggested that by repressing
SREBP2 processing 25-HC reduces Il1b transcription and represses
IL1-activating inﬂammasomes [24]. Reboldi et al. concluded that
25-HC is a critical mediator in the negative-feedback pathway of
IFN signalling on IL1-family cytokine production and inﬂamma-
some activity [24]. This data suggests that reduced synthesis of 25-
HC, or its enhanced metabolism, may be involved in the etiology of
autoimmune disease.
1.2. 7a,25-Dihydroxycholesterol is a ligand to the G-Protein coupled
receptor - EBI2
7a,25-diHC is usually formed by CYP7B1 mediated hydroxyl-
ation of 25-HC. It is present at low levels in both plasma (<ng/mL)
and CSF (<ng/mL) [25]. It was found in two independent studies by
the pharmaceutical companies Johnson & Johnson [26] and
Novartis [27], who published back-to-back papers in Nature in 2011,
that 7a,25-diHC is a ligand to the G-protein-coupled receptor
(GPCR) EBI2 or GPR183. 7a,25-diHC was found to be a potent
agonist of EBI2 and to act as chemoattractant for immune cells
expressing EBI2 by directing cell migration in vitro and in vivo.
Similar to EBI2 receptor knockout mice, mice deﬁcient in Ch25h
failed to position activated B cells within the spleen to the outer
follicle and mount a reduced plasma cell response after an immune
challenge indicating that the EBI2-oxysterol signalling pathway has
an important role in the adaptive immune response [27]. The
identiﬁcation of 7a,25-diHC as the natural ligand for EBI2 was
achieved by activity-based puriﬁcation linked with electrospray
ionisation (ESI) - high resolution MS. Accurate mass measurements
allowed identiﬁcation of ions corresponding to [MþHeH2O]þ,
[MþHe2H2O]þ, [MþNa]þ and [MþCH3CO2]- of the molecule (M) of
formula C27H46O3. Database searches for this formula revealed a
dihydroxycholesterol. Of the compounds tested both 7a,25-diHC
and 7b,25-diHC were found to activate the EBI2 receptor. NMR
analysis of puriﬁed material identiﬁed 7a,25-diHC as the endoge-
nous compound [27].
1.3. 7b,26-Dihydroxycholesterol and cholesterol precursors are
agonists towards RORgt
The RAR-related orphan receptor gamma t (RORgt) is a nuclear
receptor required for generating IL-17-producing CD4(þ) Th17 T
cells, which are essential in host defence and may play key path-
ogenic roles in autoimmune diseases. Soroosh et al. using EADSA
technology were able to identify 7b,26-dihydroxycholesterol
(7b,26-diHC, also commonly called 7b,27-dihydroxycholesterol,
Fig. 1) as an agonist of RORgt which could be synthesised by in vitro
differentiated Th17 cells [28]. Note we use here the systematic
nomenclature where hydroxylation of the terminal carbon of
cholesterol is at C-26 [29]. This ﬁnding still further highlights the
involvement of oxysterols in the immune system.
Two other groups have also found sterols to be ligands to RORgt.
Santori et al. by overexpression, RNAi, and genetic deletion of
metabolic enzymes found a cholesterol biosynthetic intermediate
downstream of lanosterol and upstream of zymosterol to activate
RORgt [30]. Immunoprecipitation of RORg followed by LC-MS and
GC-MS analysis of bound lipids identiﬁed a compound with mass
compatible of a hydroxylanosterol, but exact identiﬁcation was not
achieved. In a further study, Hu et al. found the cholesterol pre-
cursor desmosterol to be an endogenous RORg agonist [31].
1.4. 24S,25-Epoxycholesterol in Parkinson's disease and
cholestenoic acids in motor neuron disease
In 2009 Sacchetti et al. reported that an unknown compound
promoted ventral midbrain neurogenesis in vivo and in human
embryonic stem cells through activating the LXR nuclear receptor
[32]. In collaboration with Ernest Arenas' group at Karolinska
Institute we sought to identify the active molecule. By analysing
ventral midbrain from embryonic mouse we found using EADSA
and LC-MSn high levels (400 ng/g) of the LXR agonist 24S, 25-
epoxycholesterol (24S, 25-EC) and conﬁrmed that this molecule
promoted dopaminergic neurogenesis (Fig. 1) [33]. 24S, 25-EC
promoted dopaminergic differentiation of embryonic stem cells,
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Fig. 1. Synthesis and metabolism of repressors of SREBP processing and LXR ligands, 24S,25-EC, 25-HC, of the EBI2 ligand 7a,25-diHC and of the RORgt ligand 7b,26-diHC. Shown in
the inset is 24S-HC, a repressor of SREBP processing and an LXR ligand formed from cholesterol by the enzyme CYP46A1. Full stereochemistry is shown only for the initial sterols in
the pathways. Systematic names given in parenthesis. Enzymes are indicated where known. A broken arrows indicates a postulated pathway with associated enzyme.
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suggesting that LXR ligands may contribute to the development of
cell replacement therapies for Parkinson's disease (PD).
Not only are LXR ligands likely to be important in dopaminergic
neurogenesis, Andersson et al. have shown that deletion of LXRb,
the predominant isoform in the central nervous system (CNS), re-
sults in adult-onset motor neuron degeneration [34]. What might
then be the LXR ligand which is protective towardsmotor neurons?
Clues to the answer to this question come from the disorder called
hereditary spastic paresis type 5 (SPG5) which is a genetic disorder
which presents with motor neuron loss. From analysis of plasma
and CSF of patients with SPG5 we found that levels of the choles-
terol metabolite 3b,7a-dihydroxycholest-5-en-(25R)26-oic acid
(3b,7a-diHCA, Fig. 2) are reduced (in plasma from 39.40 ± 3.95 ng/
mL, mean ± SE, in controls to 5.21 ± 3.09 ng/mL in SPG5 patients
and in CSF from 2.12 ± 0.39 ng/mL in controls to 0.47 ± 0.44 ng/mL
in SPG5 patients) [25]. This is a consequence of mutations in the
CYP7B1 gene. We were able to show that 3b,7a-diHCA promoted
motor neuron survival in an LXR-dependent manner, and that
another metabolite elevated in SPG5, 3b-hydroxycholest-5-en-
(25R)26-oic acid (3b-HCA, elevated in plasma to 368.40 ± 65.27 ng/
mL from 81.12 ± 4.31 ng/mL in controls, and in CSF to
20.14 ± 2.76 ng/mL from 0.96 ± 0.10 ng/mL in controls), was toxic
towards motor neurons. Our results indicate that speciﬁc choles-
tenoic acids selectively work on motor neurons, to regulate the
balance between survival and death [25].
1.5. 24S-Hydroxycholesterol in the CNS and other tissue
24S-Hydroxycholesterol (24S-HC) is synthesised in neurons of
the CNS from cholesterol via the enzyme CYP46A1 [13]. It has been
suggested as a potential marker of neurodegeneration [3]. Neuro-
degeneration can be associated with increased levels of 24S-HC and
26-hydroxycholesterol (26-HC, commonly called 27-
hydroxycholesterol, 27-HC) in CSF, probably due to the release of
oxysterols from dying neuronal cells or in the case of 26-HC due to
defects in the blood brain barrier (BBB). On the other hand con-
centrations of 24S-HC in the circulation can reﬂect the number of
biologically active neurons and CNS cholesterol turnover [3].
Recently, Bj€orkhem et al. have found using classical GC-MS
methods that concentrations of 24S-HC in CSF of PD patients
correlate with the duration of the disease but plasma levels are
within the normal range [35]. In a similar study investigating the
effect of natalizumab treatment on oxysterol levels in patients with
relapsing remitting multiple sclerosis, again using classical GC-MS
methods, Novakova et al. found that drug treatment reduced the
levels of 24-HC and 26-HC in CSF following treatment. This was
explained by reduced neuronal damage and restored BBB integrity
upon treatment [36].
In 2006 David Russell's group at University of Texas South-
western Medical Center showed that knock out of Cyp46a1 in mice
resulted in severe deﬁciencies in spatial, associative and motor
learning [37]. It was suggested that a continuous formation of 24S-
HC is required for a sufﬁcient ﬂux through the mevalonate pathway
for formation of adequate levels of isoprenoids, such as ger-
anylgeraniol, critical for memory function [37]. Bj€orkhem's group in
Sweden have now generated a homozygous mouse overexpressing
human HA-tagged CYP46A1 [38]. Unsurprisingly, plasma levels of
24-HC, as determined by classical GC-MS methods, were elevated
6e7 fold and also elevated in brain from 31 ± 1 ng/mg tissue inwild
type (wt) to 40 ± 0 ng/mg tissue in the homozygous overexpressing
animals. Lanosterol, a marker of cholesterol biosynthesis, was
signiﬁcantly increased in brain of the homozygous overexpressing
animals, but cholesterol in brain was not signiﬁcantly different
betweenwt and transgenic animals [38]. When tested in theMorris
water maze, 15 month old female animals showed an improvement
in spatial memory. These results indicate that ﬂux through the
mevalonate pathway is important for cognitive functions in brain.
Fig. 2. Early steps of the “acidic” bile acid biosynthesis pathway generating 3b-HCA
and 3b,7a-diHCA, two cholestenoic acids regulating the survival and death of motor
neurons. Full stereochemistry is shown only for the initial sterol in the pathway.
Systematic names given in parenthesis. Enzymes are indicated where known.
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Mounting evidence indicates that CYP46A1 is expressed in cells
other than neurons. In a very recent study exploiting EADSA for
oxysterol analysis Soncini et al. found 24S-HC increased in the
pancrease of a mouse model of pancreatic neuroendocrine tumour
(pNET) development [39]. They showed that hypoxia inducible
factor (HIF-1a) controls the over expression of CYP46A1 in the
mouse model of pNET which ultimately leads to induction of the
angiogenic switch through positioning of proangiogenic neutro-
phils in proximity of CYP46A1þ islets [39].
1.6. Oxysterols and the Hedgehog signalling pathway
In the sections above, the involvement of oxysterols in the im-
mune and nervous systems has been discussed. Molecules with
similar, but not exactly the same structures are also of great
importance in the Hedgehog (Hh) signalling pathway which con-
trols numerous aspects of embryonic patterning and regeneration
of postembryonic tissues [40e42]. Insufﬁcient Hh signalling can
result in a range of birth defects, and inappropriate pathway ac-
tivity is linked to human malignancies such as basal cell carcinoma
and medulloblastoma. The pathway is activated by binding of the
cholesterol modiﬁed Hh protein to its receptor protein Patched 1
(Ptch1). This releases inhibition on the oncoprotein Smoothened
(Smo) by Ptch1, with resultant pathway activation. The Hh pathway
is modulated through Smo by a number of mechanisms, (i) there is
a requirement for cellular sterols, (ii) the pathway is activated by
speciﬁc oxysterols and (iii) the pathway may be inactivated or
activated by binding of ligands at the so called cyclopamine binding
pocket. Smo is a seven transmembrane protein with an extracel-
lular cysteine rich domain (CRD). It belongs to the GPCR family and
shows structural similarity to the Frizzled (Fz) Wnt receptors.
Cyclopamine is a plant alkaloid with an A/B ring system similar to
that found in cholesterol, and its binding pocket is within the
transmembrane domain (TMD) of Smo. On the other hand, oxy-
sterols which activate Smo bind to the extracellular CRD [40e42].
Very recently, Byrne et al. have shown that the putative oxysterol
binding site in the CRD of Smo can also bind cholesterol which
occupies the CRD groove stabilising a resting conformation poised
to respond to Hh signals. Byrne et al. suggested that oxysterols can
displace cholesterol and produce a conformational change that
leads to Smo activation [43]. Interestingly, the CRD of the Niemann-
Pick C1 (NPC1) protein also binds cholesterol (see below). 20S-
Hydroxycholesterol (20S-HC, Fig. 3) has been known for some time
as an activator of Hh signalling through interacting with Smo. This
is believed to be at the CRD. However, 20S-HC has only once been
reported as an endogenous molecule in animals and this ﬁnding
has not been conﬁrmed subsequently [44,45]. Smith-Lemli-Opitz
syndrome (SLOS, see below) is an autosomal recessive disorder
which can present with features compatible with disordered Hh
signalling [46]. It is characterised by deﬁciency in the enzyme 7-
dehydrocholesterol reductase (DHCR7), leading to elevated con-
centrations of 7-dehydrocholesterol (7-DHC) and 7-oxocholesterol
(7O-C) in the circulation. 7O-C can be further metabolised to both
26-hydroxy-7-oxocholesterol (26H,7O-C, commonly called 27-
hydroxy-7-oxocholesterol) and 25-hydroxy-7-oxocholesterol
(25H,7O-C, Fig. 3) [47]. Myers et al. have shown that both
26H,7O-C and 25H,7O-C activate the Hh signalling pathway by
binding to the CRD of Smo [40]. In contrast to these two dihy-
droxycholest-5-en-7-one sterols, another cholesterol derivative
3b,5a-dihydroxycholest-7-en-6-one (DHCEO, Fig. 3) also derived
from 7-DHC, but by free radical oxidation, has been found to be an
inhibitor of Hh signalling, apparently by a mechanism distinct from
that employed by side-chain oxysterols [48]. As over activity of the
Hh pathway is linked to some cancers, and inhibitors of Smo which
act by binding to the cyclopamine pocket of the TMD have been
approved as anti-cancer drugs, the discovery of DHCEO as an in-
hibitor of Hh signalling may provide a new lead for anticancer drug
development. In this regard we have found that 3b-hydroxy-7-
oxocholest-5-en-(25R)26-oic acid (3bH,7O-CA), a metabolite of
26H, 7O-C, is an inhibitor of Hh signalling, presumably through
interaction with Smo at the CRD binding pocket [47].
1.7. Oxysterols and breast cancer
Two papers published in November 2013 describe a link be-
tween 26-HC and breast cancer [49,50]. Nelson et al. found that 26-
HC promoted tumour growth and metastasis in mouse models of
breast cancer by acting via the estrogen receptor a (ERa) and LXR,
respectively [49]. Aggressive breast cancers were found to express
high levels of CYP27A1, the enzyme converting cholesterol to 26-
HC (Fig. 4), indicating that 26-HC within tumours may contribute
to the disease. Nelson et al. speculated that lowering circulating
levels of 26-HC or inhibiting its synthesis by CYP27A1 may offer a
strategy to prevent or treat breast cancer [49]. In the second paper,
Wu et al., found that 26-HC stimulates MCF-7 cell xenograft growth
in mice [50]. In ERþ breast cancer patients the 26-HC content in
normal breast tissue was increased compared to that in cancer-free
controls, and tumour 26-HC content was further elevated [50]. In
this second study oxysterol measurements were made by LC-MS
using the methodology outlined in Ref. [51]. In a more recent
study, Simigdala et al. found by global gene expression studies that
the cholesterol biosynthesis pathway was up-regulated in
ERþ long-term estrogen deprivation (LTED) cell lines but not ERe
LTED cell lines [52]. ERþ breast cancer cells express ERa, while ER-
cells do not. LC-MS analysis, exploiting EADSA, revealed elevated
levels of 25-HC in MCF7 LTED cells. Further studies showed that
exogenous 25-HC or 26-HC increased ER-mediated transcription
and expression of endogenous estrogen-regulated genes [52]. The
authors concluded that elevated levels of 25-HC or 26-HC may
explain resistance to endocrine therapy in ERþ breast cancer pa-
tients and has potential as a therapeutic target [52].
While 25-HC and 26-HC are implicated in the cause of breast
cancer, another oxysterol, dendrogenin A (DDA) may be an
important tumour suppressor. DDA is formed by the stereo speciﬁc
nucleophilic addition of histamine to cholesterol-5a,6-epoxide
(5a,6-EC, Fig. 4) and Poirot and colleagues have shown that DDA
causes cancer cell differentiation and has anticancer properties
both in vitro and in vivo [53]. 5a,6-EC is usually thought of as a non-
enzymatic product of cholesterol, but there is some evidence for its
enzymatic formation [54,55]. 5a,6-EC and its epimer, 5b,6-EC, are
both ligands to the microsomal antiestrogen binding site (AEBS), a
hetero-oligomeric protein to which tamoxifen, a drug which binds
to the ERa receptor, also binds. The AEBS shows cholesterol-5,6-
epoxide hydroxylase (ChEH) activity, converting 5,6-EC to choles-
tane-3b,5a,6b-triol (C-triol) and inhibition of ChEH activity by e.g.
tamoxifen, induces cancer cell re-differentiation through accumu-
lation of the DDA precursor 5a,6-EC and its epimer [53]. Interest-
ingly, the AEBS is made up of two subunits, 3b-hydroxysteroid-
D8,D7-isomerase (D8D7I) and DHCR7, two enzymes of the choles-
terol biosynthesis pathway. Using LC with nano-ESI-MS de Medina
et al. characterised DDA in mouse brain, the multiple nitrogens on
the histamine tail facilitating ionisation, and determined reduced
concentrations in breast tumours compared to controls [53].
Furthermore, DDA was not present in breast cancer or melanoma
cell lines. It seems likely that the anticancer action of DDA is
through the immune system as DDA treatment was found to
stimulate T lymphocytes and dendritic cells inﬁltration of engrafted
tumours in mice [53].
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Fig. 3. Synthesis and metabolism of oxysterol modulators of Hh signalling. Some of the oxysterols are prevalent in patients suffering from NP-C disease or SLOS. Full stereo-
chemistry is shown only for the initial sterols in the pathways. Systematic names given in parenthesis. Enzymes are indicated where known. Broken arrows indicate postulated
pathway and enzyme.
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1.8. Niemann-Pick type C disease
Niemann-Pick type C (NP-C) disease is characterised by
cholesterol accumulation in lysosomes and aberrant regulation of
cholesterol homeostasis. It is an autosomal recessive disorder with
progressive neurodegeneration leading to death in early childhood.
Two proteins implicated in NP-C are the 13-transmembrane NPC1
and the secreted NPC2. Interestingly, NPC1 shares signiﬁcant ho-
mology with Ptch1 [56] and also has a lipid binding protein fold
conserved within N-terminal CRDs of Fz receptors, which include
Smo [57]. In 2001 Alvelius et al. found high levels of bile acids with
a 3b-hydroxy-5-ene structure carrying a 7-oxo or 7b-hydroxy
group in urine and plasma from an NP-C patient by exploiting GC-
MS and nano-ESI-MS methods (Fig. 3) [58]. Since then, 7O-C, a
precursor of both the 7-oxo and 7b-hydroxy acids has been pro-
posed as a plasma biomarker for NP-C disease [59]. Formation of
the former acid proceeds through 26H,7O-C (Fig. 3), which is a
ligand to Smo as discussed above, while the latter acid can also be
generated through the same pathway but also via 7b,26-diHC
(Fig. 1). The linkage between NPC1, Ptch and Smo proteins and
the NP-C and SLOS metabolite 26H,7O-C is very intriguing.
Besides 7O-C, C-triol has been shown to be a biomarker for NP-
C, and methods have been developed based on GC-MS [59] and LC-
MS with derivatisation to dimethylglycine esters for its analysis
(see below) [12,60]. Using this derivatisation method and LC-MS,
Klinke et al. demonstrated that not only NP-C, but also NP-A and
NP-B, which have a similar clinical picture to NP-C, show elevated
levels of 7O-C and C-triol in plasma [61]. A danger of making a
clinical diagnosis based on 7O-C and C-triol is that the former is a
direct autoxidation product of cholesterol, while the latter can be
formed by hydrolysis of 5,6-EC, which may similarly be formed via
autoxidation. Autoxidation of cholesterol can occur during sample
handling in air [62].
To avoid the problem of autoxidation, Mazzacuva et al. have
developed an LC-MS method utilising negative-ion ESI for the
analysis of the conjugated bile acids 3b-hydroxy,7b-N-acetylglu-
cosaminylchol-5-enoic acid (Fig. 3) and 3b,5a,6b-trihydrox-
ycholanoyl-glycine (Fig. 4) both of which accumulate in NP-C
plasma and are enzymatically derived metabolic products of 7O-C
and C-triol, respectively [63]. As the GlcNAc transferase, UGT3A1, is
commonly mutated and inactive, 3b,5a,6b-trihydroxycholanoyl-
glycine was concluded to be the better marker of NP-C [63]. A
second piece of evidence for this conclusion is that we have
recently shown that 3b-hydroxy, 7b-N-acetylglucosaminylchol-5-
enoic acid is also a metabolic product found in patients with SLOS
[47].
Fig. 4. Oxysterols implicated in the cause of cancer and metabolism of 5,6-EC. Full stereochemistry is shown only for the initial sterol in the pathways. Systematic names given in
parenthesis. Enzymes are indicated where known. Broken arrows indicate postulated pathway.
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1.9. Smith-Lemli-Opitz-syndrome
SLOS is a severe autosomal recessive disorder resulting from
defects in the cholesterol synthesising enzyme DHCR7, leading to a
build-up in the cholesterol precursor 7-DHC and its isomer 8-DHC
in tissues and blood plasma (Figs. 3 and 5) [46]. The phenotypic
spectrum of SLOS is very broad. Severe cases die in utero, mild cases
show only minor physical, learning and behavioural problems.
Limb abnormalities are, however, common in SLOS patients [46].
For diagnosis, levels of 7-DHC are usually measured by GC-MS,
however, recently Liu et al. have developed an LC-MS method
based on derivatisation with 4-phenyl-1,2,4-triazoline-3,5-dione
(PTAD, Fig. 6) through a Diels-Alder cycloaddition which is appli-
cable for analysis of sterols with a 5,7-diene structure as in 7-DHC
(see below) [9].
Using LC-MSn incorporating EADSA technology we recently
proﬁled oxysterols derived from 7-DHC and 8-DHC in human
plasma [64]. We found a novel hydroxy-8-dehydrocholesterol,
where hydroxylation was either at C-24 or C-25 [64], and also
identiﬁed the known metabolites 26-hydroxy-8-
dehydrocholesterol [65], 4-hydroxy-7-dehydrocholesterol [66],
7a,8-epoxycholesterol (7a,8-EC) [67] and DHCEO [68] (Fig. 5). None
of these metabolites were detected in control plasma at quantiﬁ-
able levels (0.5 ng/mL) [64]. Importantly, this was the ﬁrst identi-
ﬁcation of DHCEO in human plasma, although it has been found to
be a major product of 7-DHC free radical oxidation in tissues and
ﬂuids from a rat model of SLOS [69]. We also found elevated levels
of 7O-C in SLOS plasma [67], in agreement with an earlier study by
Liu et al. [66]. Shinkyo et al. have shown that 7O-C can be formed
from 7-DHC by CYP7A1 (Fig. 3), this explains its high level in SLOS
plasma [70], 7a,8-EC is formed as a side-product to this reaction
(Fig. 5) [67,70]. In a very recent study, using LC-MSn and EADSA, we
have found that 7O-C can be further metabolised in SLOS patients
to 26H,7O-C and also 25H,7O-C, and that the former compound can
be metabolised further to 3bH,7O-CA (Fig. 3) [47]. Importantly,
SLOS is a genetic disease that phenocopies aberrant Hh signalling
and 26H,7O-C and 25H,7O-C are activators of Hh signalling [40]
while 3b,7O-CA is an inhibitor [47].
2. Analytical improvements
Since our review of “Oxysterol Metabolomes” in 2011 [7], there
have been a number of improvements in analytical methods for the
analysis of oxysterols and related compounds. McDonald and col-
leagues in Dallas have reﬁned their LC-MS methods which are now
applicable for analysis of more than 50 sterols and oxysterols from
only 200 mL of plasma with detection limits of 1 ng/mL [8,51]. In an
effort to improve sensitivity, there has been a revival of interest of
exploiting derivatisation chemistry to enhance LC-MS analysis of
oxysterols. Our preference is for EADSA where oxysterols are ﬁrst
oxidised at C-3 to a 3-oxosteroid, usually by conversion of the 3b-
hydroxy group to a 3-oxo with cholesterol oxidase, then reaction
with the Girard P (GP) reagent to enhance ESI signal and direct
fragmentation upon MS/MS or MSn (Fig. 6) [11,71]. A disadvantage
of this method is that it requires duplicate analysis, (a) with, and (b)
without, addition of cholesterol oxidase to differentiate between
compounds that naturally contain a 3-oxo group and those that
naturally contain a 3b-hydroxy group (see Fig. 6B). We have now
introduced a [2H5]GP reagent which allows the (a) and (b) fractions
to be analysed simultaneously by LC-MSn. Derivatisation with Gir-
ard reagents offers improved speciﬁcity and sensitivity and this has
been exploited by other groups using mainly the Girard T (GT) re-
agent rather than GP [28,39,52]. Impressively, using EADSA and GT
derivatisation Roberg-Larsen et al. were able to show that 26-HC is
elevated in exosomes from an ERþ breast cancer cell line derived
from only 200,000 cells [72]. This group use low ﬂow-rate chro-
matographywith ESI to enhance sensitivity and incorporate on-line
solid-phase extraction for sample clean-up. Of the various other
derivatisation methods, the one developed by Jiang et al. [73]
where the free hydroxy group(s) is derivatised with N,N-dime-
thylglycine (DMG) has become popular for identiﬁcation of NP-C
disease (Fig. 6C) [12,61]. This method suffers from an inherent
lack of speciﬁcity on account of the prevalence of hydroxy-
containing molecules in nature. An alternative derivatisation tar-
geted at hydroxy groups is derivatisation to picolinic acid esters
[74] or nicotinic acid esters [10]. Sidhu et al. have exploited the
latter derivatisation to analyse oxysterols in CSF and plasma [10]
(Fig. 6C).
Fig. 5. Some primary products of 7-DHC oxidation found in patients with SLOS. Further metabolic products are shown in Fig. 3. Full stereochemistry is shown only for the initial
sterol in the pathways. Systematic names given in parenthesis. Enzymes are indicated where known. Broken arrows indicate postulated pathway.
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Fig. 6. Derivatisation reactions for sterol and oxysterol analysis by LC-MS (A) Derivatisation with PTAD. (B) Derivatisation with GP reagent. (C) Left hand side, derivatisation with
dimethylglycine; right hand side, derivatisation with nicotinic acid. Abbreviations: DMAP, 4-(dimethylamino)pyridine; DMG, N,N-dimethylglycine; EDC, 1-ethyl-3-(3-dimethyl-
aminopropyl) carbodiimide; DPC, N,N-diisopropylcarbodiimide.
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A new derivatisation for sterols in general is reaction with PTAD
(Fig. 6A). Although this derivatisation is well known for vitamins D
analysis, Liu et al. have shown that it can be used for unsaturated
sterols in general [9]. By careful choice of conditions, the reaction
can be “tuned” to favour reaction with B-ring unsaturated sterols
like cholesterol via an “ene” reaction, or with side-chain double
bonds as in desmosterol, also via an “ene” reaction, or with con-
jugated dienes like 7-DHC in a Diels-Alder reaction. The PTAD
derivatisation offers improvement in sensitivity and also provides a
route to stabilising reactive dienes [9].
Matrix-assisted laser desorption/ionisation (MALDI)-MS imag-
ing is an exciting technology for determining the location of mol-
ecules in a tissue. By coating tissue, e.g. 10 mm thick coronal section
of rodent brain, with matrix and mounting the tissue on a stage
then moving the stage relative to the laser, it is possible to record
mass spectra at discrete pixels and reconstruct an image of a spe-
ciﬁc ion over the tissue. However, as in all MS, only molecules that
can be ionised will be observed. Cobice et al. have cleverly exploited
GT derivatisation to image 7O-C in mouse brain [75]. In the absence
of GT derivatisation any signal from 7O-C is hidden by back-ground
noise. Cobice et al. found that by using GT derivatisation a signiﬁ-
cant increase in 7O-C signal was observed in brain sections from
hydroxysteroid dehydrogenase (HSD) 11B1 deﬁcient mice [75].
HSD11B1 is the enzyme which converts 7O-C to 7b-HC and in its
absence 7O-C accumulates.
3. Conclusions
When the authors joined the ﬁeld of oxysterol analysis around
the turn of the century, oxysterols and cholestenoic acids were
mostly considered as uninteresting intermediates of cholesterol
metabolism. Some oxysterols had been shown to have biological
activity, but the most studied oxysterol, 25-HC, was detected at low
levels in biological samples, and was often suspected to be an
artefact of sample handling [62]. Despite notable exceptions
[3,62,76e79] few researchers were interested in the biochemistry
of oxysterols. However, in the last 5e10 years we have seen a
paradigm shift, with a huge surge of interest in oxysterol
biochemistry. There have been major developments in MS tech-
nology and methods for oxysterol analysis, but problems still are
evident. Oxysterols can be formed from cholesterol in air, so there is
always the danger of their artefactual formation through sample
handling. There are a huge number of isomeric oxysterols. We now
know that not only is 7a,26-diHC a biologically relevant molecule
on the pathway to bile acid biosynthesis, but is its epimer, 7b,26-
diHC, is also biologically relevant. Similarly, both 24S-HC and
24R-HC can be found in biological samples [80]. The analyst must
be aware of the huge potential for isomeric structures or important
molecules will be missed or misidentiﬁed and if chromatographic
separation is inadequate quantitation will be inaccurate. Despite
these reservations the future for cholesterolomics is bright.
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